Valuation: Shanghai Rendu Biotechnology Co., Ltd.

Market Cap 2.02B 302M 268M 250M 228M 430M 29.02B 434M 3.03B 1.17B 14.83B 1.13B 1.11B 47.61B P/E 2024
-179x
P/E 2025 186x
Enterprise Value 1.21B 180M 160M 150M 136M 257M 17.34B 260M 1.81B 701M 8.86B 677M 662M 28.45B EV / Sales 2024
3.31x
EV / Sales 2025 6.55x
Free-Float
48.41%
Yield 2024
0.56%
Yield 2025 2.38%
08-28 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
05-14 Shanghai Rendu Biotechnology's share trade to resume from May 15 RE
05-13 Nanjing Haijing Pharmaceutical Co., Ltd. agreed to acquire 21.25% stake in Shanghai Rendu Biotechnology Co., Ltd. from Ju Jinliang, Qiming Weichuang Venture Capital Management Company Limited, Runcong Enterprise Management Center (Limited Partnership), China International Capital Corporation Limited, Qiming Ventures Fund III, Changzhou Jinxin Venture Capital Co., Ltd. and Novel Praise Limited for approximately CNY 520 million. CI
05-08 Rendu Biotech's Controlling Shareholder Eyes Share Transfer Deal MT
05-07 Trading in Shanghai Rendu Biotechnology's shares to halt RE
04-28 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
30/10/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
29/08/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
29/04/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/02/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
29/10/24 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
29/08/24 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 CI
1 day+4.46%
1 week+6.12%
1 month+4.32%
3 months+0.71%
6 months-0.34%
Current year+7.90%
1 week 48.58
Extreme 48.58
55.06
1 month 42.33
Extreme 42.33
55.06
Current year 40
Extreme 40
63.56
1 year 40
Extreme 40
63.56
3 years 22.5
Extreme 22.5
63.56
5 years 22.5
Extreme 22.5
72
10 years 22.5
Extreme 22.5
72
Manager TitleAgeSince
Chief Executive Officer 43 08/12/2022
Chief Tech/Sci/R&D Officer 60 12/06/2007
Director of Finance/CFO 52 31/07/2015
Director TitleAgeSince
Chairman 60 12/06/2007
Director/Board Member 43 30/04/2008
Director/Board Member 61 20/10/2020
Change 5-day change 1-year change 3-year change Capi.($)
+4.46%+6.12%+10.60%+10.01% 301M
+0.70%-3.98%-26.87%+1.60% 167B
+0.46%-2.11%-9.12%+11.57% 111B
+1.21%+1.45%-24.59%+0.91% 105B
-1.24%-0.76%-49.04%-12.75% 74.82B
-0.41%+0.19%-0.35%+71.71% 59.11B
-0.86%+4.49%+17.49%+57.78% 51.8B
-0.96%-4.10%-7.99%-31.61% 48.5B
+0.58%+0.30%-17.83%+20.85% 40.79B
-1.35%-1.77%+28.07%-10.01% 32.54B
Average +0.27%+0.53%-7.96%+12.01% 69.05B
Weighted average by Cap. +0.11%-0.91%-16.02%+10.02%

Financials

2024 2025
Net sales 177M 26.45M 23.5M 21.94M 19.99M 37.71M 2.54B 38.06M 265M 103M 1.3B 99.31M 97.16M 4.17B 162M 24.15M 21.46M 20.03M 18.26M 34.43M 2.32B 34.75M 242M 93.93M 1.19B 90.68M 88.71M 3.81B
Net income -7.81M -1.17M -1.04M -966K -881K -1.66M -112M -1.68M -11.69M -4.53M -57.26M -4.37M -4.28M -184M 10.09M 1.5M 1.34M 1.25M 1.14M 2.14M 145M 2.16M 15.1M 5.85M 73.94M 5.65M 5.53M 237M
Net Debt -798M -119M -106M -98.64M -89.9M -170M -11.43B -171M -1.19B -463M -5.85B -447M -437M -18.76B -815M -121M -108M -101M -91.82M -173M -11.68B -175M -1.22B -472M -5.97B -456M -446M -19.16B
Logo Shanghai Rendu Biotechnology Co., Ltd.
Shanghai Rendu Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production, and sales of molecular diagnostic reagents and equipment. The Company mainly operates three businesses. The reagent business is mainly engaged in the research, development, production, and sales of molecular diagnostic reagents for reproductive tract infections, respiratory tract infections, enteroviruses, and bloodborne infectious diseases, as well as other reagent products such as sample preservation solutions and nucleic acid extraction reagents. The instrument business is mainly engaged in the research, development, production, and sales of molecular diagnostic instruments such as the fully automated nucleic acid detection and analysis system (AutoSAT). The testing business is mainly engaged in the provision of clinical testing services, including pathogen detection for the genitourinary system, bloodborne pathogens, respiratory system, and digestive system.
Employees
235
Date Price Change Volume
30/09/26 CN¥52.19 +4.46% 993,614
29/09/26 CN¥49.96 +2.34% 596,074
28/09/26 CN¥48.82 -0.73% 383,517
24/09/26 CN¥49.18 +0.57% 428,773
23/09/26 CN¥48.90 +1.07% 345,938
  1. Stock Market
  2. Stocks
  3. 688193 Stock